Wound-care product from Osiris shows positive trial results

Osiris Therapeutics reported that its Grafix wound-care product, which releases stem cells straight to the wound site to allow tissue regeneration, demonstrated effectiveness in treating patients with diabetic foot ulcers in a postmarket study. The study found that complete wound closure was achieved in 62% of patients who were treated with Grafix, compared with 21% of those who received traditional therapy.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC